The growth hormone (GH)-insulin-like growth factor-1 (IGF-1) axis has several roles. While achievement of a satisfactory height is probably the most important and well-known, it is now clear that it also affects body composition, metabolism, muscle mass, and bone density during the transition period. Recombinant-growth hormone (Rec-GH) therapy is normally administered to GH-deficient children to achieve a reasonable final height. Retesting with a provocative test (insulin tolerance test or growth-hormone-releasing hormone + arginine test) is necessary during the transition period, after measuring IGF-1 levels. If the patient is still GH-deficient, rec-GH therapy should be restarted at 0.2-0.5 mg/day up to a final dosage of 0.8-1.0 mg/day (albeit there is no general consensus on the dosage). In fact, there is widespread literature evidence of the negative impact of GH-deficiency during the transition period, which provokes increased visceral fat and waist/hip ratio, decreased muscle mass and bone density and increased cardiovascular morbidity and mortality.
low-density lipoprotein cholesterol (LDL-c) and no important increase in high-density lipoprotein cholesterol (HDL-c) widely reported. There is a very slight increase in triglyceride levels, but this does not have a great effect on metabolic profile. 13 However, another study described a significant decrease in triglyceride levels after three months of rec-GH, which had a positive correlation with changes in IGF-1 levels. 14 There is no literature evidence of significant changes to glucose-insulin metabolism. After one year of rec-GH therapy, an insignificant increase in fasting insulin and a slight decrease in insulin sensitivity was reported, but both remained within the normal range. 13 Naturally, as confirmed by the literature and our own experience, 15 better results are obtained when GH treatment is restarted during early adolescence. This aspect is very important and should motivate the endocrinologist to retest patients promptly to avoid the establishment of a more adverse lipid profile and high cardiovascular risk. 16, 17 Body composition is described by the relative proportions of fat and lean mass (LBM). The first comprises subcutaneous and visceral fat, while the second consists of water (73 % of the entire LBM) plus bone mineral mass and muscle mass. The GH-IGF-1 axis, together with sex steroids, has a significant effect on body composition, but this effect is mainly seen in cases of GHD. In fact, an important article quoted extensively in the medical literature [9] [10] [11] [12] [13] [14] [15] demonstrated that a long period of rec-GH therapy discontinuation induces a consistent increase in per cent fat mass and trunk fat, with a decrease in LBM. This aspect is also stressed by several studies that compared groups of GHD patients treated with rec-GH therapy against patients treated with placebo. 18 The effect of rec-GH on leptin and ghrelin levels is also interesting. The first is produced primarily in the adipocytes of white adipose tissue (and therefore fat mass positively correlates with leptin levels), and its circulating levels depend on the total amount of fat in the body. The role of leptin is to inhibit appetite by its counteractive effects on neuropeptide Y, a potent feeding stimulant secreted by gut and hypothalamus cells.
A lack of leptin or a genetic failure of leptin receptors leads to marked obesity. Ghrelin is mainly produced by P/D1 cells lining the fundus of the stomach and epsilon cells in the pancreas. It is considered the counterpart of leptin; as its levels increase before meals and decrease after meals, it evidently induces hunger. It is also a potent stimulator of GH production by the pituitary gland. 19 An important study by Roemmler et al. 20 demonstrated that GHD patients under long-term rec-GH replacement therapy have significantly lower leptin levels (due to lower amounts of fat mass) and slightly but not significantly higher ghrelin levels than untreated age-and BMI-matched GHD patients.
The transition period is probably best known for the accrual of peak bone mass. Here too, GH and its peripheral effector have an essential From that moment and throughout adulthood, bone mineral density (BMD) will remain in a 'steady state', before decreasing progressively and inexorably during aging. The peak bone mass reached during the transition period is therefore fundamental. In fact the higher the peak bone mass reached during puberty and transition, the lower the risk of bone fractures during aging, again demonstrating the essential role of the GH-IGF-1 axis.
It is well known that young adults with GHD have a diminished BMC and BMD. This double reduction is more marked in childhood-onset GHD (CO-GHD) than adult-onset GHD, providing further evidence of the role of the GH-IGF1 axis on the accrual of peak bone mass. 21 Stopping rec-GH therapy after final height has been achieved could lead to a significant reduction in cortical thickness, cross-sectional area and overall content.
Furthermore, markers of bone remodeling (such as bone-specific alkaline phosphatase) are raised during GH therapy in young adults with GHD. 22 However, bones may have different responses to GH, which could depend on the type of bone stimulated (cortical or trabecular). Some studies have shown a significant increase in both lumbar spine and total hip mineral density, without any evidence of improvement in other bone areas. 23 In any case the effects of rec-GH therapy on other bone areas may only become evident a considerable time later. The first outcomes of a study of the effects of 10 years of rec-GH therapy on patients with adulthood-onset GHD were observed after nine months in the lumbar spine and total body, but only after prolonged replacement therapy in the femur, probably reflecting the different actions of GH on cortical and trabecular bone. 24 During the transition period, it is very important that treatment is scheduled to last at least 9-10 months. This is due to a paradox effect induced at the start of GH-therapy, when bone mineral resorption predominates over deposition as more bone remodeling units are activated, resulting in a net loss in BMD. With the passing of time this ends and there is a progressive increment in BMD. 25 There is no clear literature consensus about the relationship between GHD, decreased BMD and higher risk of fractures. Hogler et al. concede the negative consequences of GHD on bone structure, but do not report an unquestioning association with a higher risk of fractures. In contrast, a Swedish national database demonstrated that GHD adults have a 2-3 times risk of bone fractures than gender-and age-matched normal subjects. 26, 27 The effect of rec-GH therapy (and thus of the GH-IGF-1 axis) on the reproductive system has largely been neglected. An important exception was a study by our own group, 28 as also cited in our 2011 review. 15 The study population consisted of ten infertile men with severe idiopathic oligozoospermia, normal or moderately raised blood gonadotropin and IGF-1 at low levels or within the lower limit of normal. They underwent short-term rec-GH therapy, which appeared to enhance sperm synthesized by Sertoli and Leydig cells). 30, 31 It is useful at this point to comment briefly on the safety of rec-GH therapy with respect to testicular function. A study by Bertelloni 32 is alone in reporting gonad dysfunction in short patients treated with recombinant therapy, while other studies demonstrate its total safety.
Our group 33 found that GH treatment did not affect testicular development and function in non-GHD short stature (with normal levels of IGF-1), as there is no negative influence on inhibin B values (and therefore rec-GH therapy does not affect tubular or Sertoli cell function).
In females, the GH-IGF-1 axis seems to be essential in both proliferation and differentiation of granulose cells and, as in the testis, stimulates steroidogenesis in large follicles and thecal cells. GH receptor mRNA and protein have been found in ovarian cells, suggesting that GH also has a direct, IGF-1-independent action as an important modulator of gonadotropin-dependent and -independent functions.
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Quality of Life
The irreplaceable role of GH, both during the transition period and after the QoL, such as body shape, concentration, initiative and drive, physical stamina, self-confidence, and the ability to become sexually aroused and to tolerate stress. QoL was significantly lower after rec-GH suspension, particularly with respect to body shape and sexual arousal. 36 However, another recent study disputed Attanasio's conclusions, as no evident difference in QoL was found between treated and untreated patients in a younger cohort (mean age 15 years) of CO-GHD patients. 37 To conclude this section, we note a final study which demonstrated that the psychological difficulties of a GHD group were improved by GH treatment, but reverted after the end of the treatment.
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Retesting and Proper Therapy Dosage rec-GH therapy is usually stopped when the bone growth plates shut down, in the hope that satisfactory linear growth will be achieved through the effect of the increased gonad steroids. The endocrinologist and/or pediatrician should thus request a wrist X-ray for a conclusive evaluation of bone age. A knee X-ray may also give more accurate information on growth plate status. As noted in the literature, GH-treatment is generally stopped when growth velocity decreases to <1 cm/year or after a bone age of 15 years in girls or 17 in boys is attained, indicating a remaining growth potential of <1 %.
The guidelines of the European Society for Paediatric Endocrinology
Consensus statement drawn up in collaboration with the Growth Hormone
Research Society provide a clearer description of suitable clinical conduct after rec-GH withdrawal. 2 Among the main concepts is the need for revaluation of the axis (retesting) during the transition period, from one to three months after rec-GH discontinuation. Two possibilities are described:
adolescents with CO-GHD presenting well-known mutations, congenital abnormalities, lesions or irreversible structural damage to the central nervous system (CNS), in which GH and IGF-1 must be measured and a provocative test carried out only if the baseline IGF-1 level is <-2 SD;
and idiopathic isolated GHD patients, who must be reassessed both by measuring IGF-1 and with a provocative test.
The gold-standard provocative test is GHRH + Arginine test (not recommended with childhood-onset idiopathic isolated GHD, as it may
give a false normal response in some cases). This is better than the insulin tolerance test (ITT), which is not easily repeatable due to the possibility of side effects. GHD diagnosis must be reconsidered whenever the GH response to the test is above the established cut-off, which is 6.1 mcg/l for ITT and 20 mcg/l for GHRH + Arginine. [39] [40] [41] As suggested by the Endocrine Society's Clinical Practice Guidelines, 42 rec-GH therapy should be reintroduced after a short period, usually known as a 'GH-holiday', in which retesting can be carried out. 
